Study Summary
This trial will test the safety and efficacy of the combination of VS-6063, carboplatin, and paclitaxel in patients with ovarian cancer.
- Ovarian Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 4 Secondary · Reporting Duration: 4 years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Defactinib (VS-6063) +Carboplatin/Paclitaxel
1 of 1
Experimental Treatment
90 Total Participants · 1 Treatment Group
Primary Treatment: VS-6063 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What clinical indications is VS-6063 commonly utilized for?
"Beyond its effectiveness in treating melanoma, VS-6063 has been shown to reduce the growth of neoplasm metastasis, lymphomas, and various types of sarcoma." - Anonymous Online Contributor
Is access to this research project currently available for participants?
"Indeed, current information on clinicaltrials.gov specifies that this research is actively recruiting participants. The study was first published on February 6th 2018 and was last modified January 23rd 2020; the investigators are hoping to recruit 90 people at a single location." - Anonymous Online Contributor
What further investigations have been conducted regarding the effects of VS-6063?
"In total, 1182 studies are currently underway studying the therapeutic potential of VS-6063. Of those active investigations, 332 have progressed to Phase 3 and span 68069 locations with a majority located in Shanghai." - Anonymous Online Contributor
How extensive is the scope of this experimental program?
"Correct. According to clinicaltrials.gov, this medical trial is actively seeking participants from a single location and 90 people in total. The study was first posted on February 6th 2018 with the most recent update occurring January 23rd 2020." - Anonymous Online Contributor
What are the essential goals of this trial?
"The objectives of this 4 year trial are to gauge the safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (as evaluated through adverse events), observe changes in health related quality-of-life among patients receiving treatment, document any toxicities that may arise from therapy, and record overall survival rates as per RECIST 1.1 standards." - Anonymous Online Contributor